Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA's Gottlieb Warns Congress Of Shortages, Potential Job Losses In Puerto Rico

Executive Summary

Medical-product manufacturers in Puerto Rico took a major hit from Hurricane Maria, but some are slowly getting back up to speed as portions of the island's electrical grid go back online and additional generator power is deployed by device and drug companies, FDA Commissioner Scott Gottlieb told a US congressional panel Tuesday. But he warned that some facilities are "'sole-source" providers of devices and drugs, and that some longer-term government support may be needed to prevent future product losses.

You may also be interested in...

Saline Bag Shortages Continue As Flu Season Heats Up

The shortage of medical products caused by Hurricane Maria continues even as US FDA moves expiration dates and allows more imports to fill the need.

US FDA Fights Persisting IV Supply Shortages From Hurricane Maria

The September hurricane destroyed Puerto Rican medical device plants, causing a shortage of several key products that's still being felt. FDA Commissioner Scott Gottlieb said Monday that the agency is allowing more imports and considering other tactics to ease the shortage.

Puerto Rico Tax-Haven Status, R&D Credit Weakened By Tax-Reform Bill

Under tax reform legislation recently passed by Congress, a 20% tax on products made in domestic territories will adversely affect the many device firms with Puerto Rican plants that currently enjoy a lower, 4% tax rate on profits. And a second tax provision usually relied upon by medtech companies, the R&D tax credit, also loses ground under the final Senate bill passed Dec. 2.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts